DIAGNOSTIC_TEST
hs-TnT (high-sensitive cardiac troponin T) plasma concentration
hs-TnT plasma concentration measured once every 12 hours
Status
Unknown
Phase
Not applicable
Enrollment
30
Locations
1
Results
Not posted
Publications
7
Study summary
Up to this day, little is known whether the extent of brain damage in patients with SAH correlates with the degree neurogenic myocardial injury and neurogenic lung injury. This is a prospective observational study designed to asses relationship between catecholamine surge and development of myocardial and lung injury in subarachnoid haemorrhage patients.
Multiple forms of brain damage, primarily, subarachnoid haemorrhage (SAH) are frequently accompanied by neurogenic myocardial injury with changes in the electrocardiogram, accompanied by the release of markers of myocardial injury. This form of cardiac dysfunction is thought to be mediated by cellular toxicity associated with catecholamine release. Central nervous system damage in the course of intracranial haemorrhage may, in a similar pathogenic pathway, lead to neurogenic lung injury. Up to this day, little is known whether the extent of brain damage in patients with SAH correlates with the degree of neurogenic myocardial injury. Moreover, it remains unknown what is the full clinical picture and duration of this type of myocardial injury and how often it co-occurs with neurogenic lung injury. Such analysis is a fundamental and most important step in optimising the treatment of these patients. Methods: In this prospective observational study the authors aim to recruit 30 patients with subarachnoid haemorrhage, requiring hospitalization in the Intensive Care Unit. The patients will be monitored for elevation in cardiac damage markers (hs-TnT, CPK, CK-MB, NT-proBNP) and worsening of respiratory conditions, defined by need for more invasive ventilation parameters, and subsequent changes in arterial blood gas. The above mentioned parameters will be assessed every 12 hours. Additionally, the patients will be screened for an elevation in catecholamine metabolite (metanephrine) concentration in 12-hour urine collection. Hypothesis to be tested: Myocardial and lung injury in SAH patients is timely-associated with an increase in metanephrine concentration in urine.
Interventions
DIAGNOSTIC_TEST
hs-TnT plasma concentration measured once every 12 hours
DIAGNOSTIC_TEST
CK-MB plasma concentration measured every 12 hours
DIAGNOSTIC_TEST
CPK plasma concentration measured every 12 hours
DIAGNOSTIC_TEST
NT-proBNP plasma concentration measured every 12 hours
DIAGNOSTIC_TEST
Metanephrine concentration measured in 12-hour urine collection using spectrophotometry.
Timeline
First posted
Jun 7, 2022
Study start
Jan 22, 2022
Primary completion
Jun 30, 2024
Study completion
Dec 31, 2024
Results posted
Not reported
Registry updated
May 6, 2023
Outcomes
In-hospital death (number of patients)
Time frame · 7 days
Death of the patient during the first 7 days of hospitalization.
Number of Patients with elevation in hs-TnT levels
Time frame · 7 days
hs-TnT treated as myocardial injury biomarker
Number of Patients with elevation in NT-proBNP levels
Time frame · 7 days
NT-proBNP treated as myocardial injury biomarker
Number of Patients with elevation in creatine kinase levels
Time frame · 7 days
Creatine kinase treated as myocardial injury biomarker
Number of Patients with elevation in creatine kinase MB levels
Time frame · 7 days
Creatine kinase MB treated as myocardial injury biomarker
Number of Patients with a decrease in Horowitz index
Time frame · 7 days
The decrease in Horowitz index treated as a sign of need for more invasive ventilation parameters with subsequent blood gas changes
Number of Patients with need of increased FiO2
Time frame · 7 days
Need of increased FiO2 treated as a sign of need for more invasive ventilation parameters with subsequent blood gas changes
Number of Patients with need of increased PEEP values
Time frame · 7 days
Need of increased PEEP values treated as a sign of need for more invasive ventilation parameters with subsequent blood gas changes
Not reported in the indexed record.
Eligibility
Inclusion Criteria: * patients with subarachnoid haemorrhage (both aneurysmal and non-aneurysmal) with acute consciousness disturbances (Glasgow Coma Scale \< 8 pts) requiring intubation and mechanical ventilation, hospitalized in the ICU for over 24 hours Exclusion Criteria: * severe prior pulmonary diseases * severe prior cardiac diseases * death in the first 72 hours of ICU stay * need for any extracorporeal life-saving techniques
Study locations
Poland. Showing up to 24 locations stored in the fast local snapshot.
University Clinical Center prof. K. Gibiński of the Medical University of Silesia in Katowice
Katowice, Silesian Voivodeship, Poland
Publications
Related trials
Universidade do Porto · Heart Failure
Not applicable
Recruiting
160
2026-07
Boston Medical Center · Congestive Heart Failure · Volume Overload
Not applicable
Not yet recruiting
200
2026-06
Norfolk and Norwich University Hospitals NHS Foundation Trust · Vascular Surgical Procedure
Not applicable
Recruiting
200
2026-06
China National Center for Cardiovascular Diseases · AKI - Acute Kidney Injury · Cardiac Surgical Procedures
Phase 4
Not yet recruiting
694
2026-06
Cambridge University Hospitals NHS Foundation Trust · Heart Failure
Not applicable
Recruiting
250
2026-05
Chulalongkorn University · Acute Kidney Failure Stage 3
Not applicable
Completed
100
2026-05
Ottawa Heart Institute Research Corporation · Chronic Right-Sided Heart Failure · Pulmonary Arterial Hypertension
Phase 4
Completed
15
2026-05
Novartis · Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Not applicable
Completed
236
2026-04
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.